Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone

A. Corso, A. Lorenzi, V. Terulla, F. Airò, M. Varettoni, S. Mangiacavalli, P. Zappasodi, C. Rusconi, M. Lazzarino

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Deep venous thrombosis (DVT) has been variably reported in multiple myeloma patients during treatment with thalidomide alone or in combination with chemotherapy or dexamethasone. With the aim of investigating this complication, we performed, on a cohort of 13 relapsed refractory MM patients treated with low-dose thalidomide (100 mg/day) and dexamethasone (20 mg p.o./day for 4 days every 2 weeks), a serial evaluation of different laboratory parameters implicated in DVT. No significant abnormalities in all genetic, serologic, or plasmatic parameters studied were registered, apart from thrombomodulin which showed significant variations between baseline and 1st-month values and 1st- and 3rd-month values. In conclusion, the evidence of significant variations of thrombomodulin values in the 1st month of therapy, which is considered to involve the highest risk of thrombosis, might support a role for thrombomodulin in this complex mechanism.

Original languageEnglish
Pages (from-to)588-591
Number of pages4
JournalAnnals of Hematology
Volume83
Issue number9
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Thrombomodulin
Thalidomide
Dexamethasone
Venous Thrombosis
Combination Drug Therapy
Multiple Myeloma
Thrombosis
Therapeutics

Keywords

  • Deep venous thrombosis
  • Dexamethasone
  • Multiple myeloma
  • Thalidomide therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. / Corso, A.; Lorenzi, A.; Terulla, V.; Airò, F.; Varettoni, M.; Mangiacavalli, S.; Zappasodi, P.; Rusconi, C.; Lazzarino, M.

In: Annals of Hematology, Vol. 83, No. 9, 09.2004, p. 588-591.

Research output: Contribution to journalArticle

@article{265c34f919834b53a109c92f99b3f386,
title = "Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone",
abstract = "Deep venous thrombosis (DVT) has been variably reported in multiple myeloma patients during treatment with thalidomide alone or in combination with chemotherapy or dexamethasone. With the aim of investigating this complication, we performed, on a cohort of 13 relapsed refractory MM patients treated with low-dose thalidomide (100 mg/day) and dexamethasone (20 mg p.o./day for 4 days every 2 weeks), a serial evaluation of different laboratory parameters implicated in DVT. No significant abnormalities in all genetic, serologic, or plasmatic parameters studied were registered, apart from thrombomodulin which showed significant variations between baseline and 1st-month values and 1st- and 3rd-month values. In conclusion, the evidence of significant variations of thrombomodulin values in the 1st month of therapy, which is considered to involve the highest risk of thrombosis, might support a role for thrombomodulin in this complex mechanism.",
keywords = "Deep venous thrombosis, Dexamethasone, Multiple myeloma, Thalidomide therapy",
author = "A. Corso and A. Lorenzi and V. Terulla and F. Air{\`o} and M. Varettoni and S. Mangiacavalli and P. Zappasodi and C. Rusconi and M. Lazzarino",
year = "2004",
month = "9",
doi = "10.1007/s00277-004-0891-6",
language = "English",
volume = "83",
pages = "588--591",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone

AU - Corso, A.

AU - Lorenzi, A.

AU - Terulla, V.

AU - Airò, F.

AU - Varettoni, M.

AU - Mangiacavalli, S.

AU - Zappasodi, P.

AU - Rusconi, C.

AU - Lazzarino, M.

PY - 2004/9

Y1 - 2004/9

N2 - Deep venous thrombosis (DVT) has been variably reported in multiple myeloma patients during treatment with thalidomide alone or in combination with chemotherapy or dexamethasone. With the aim of investigating this complication, we performed, on a cohort of 13 relapsed refractory MM patients treated with low-dose thalidomide (100 mg/day) and dexamethasone (20 mg p.o./day for 4 days every 2 weeks), a serial evaluation of different laboratory parameters implicated in DVT. No significant abnormalities in all genetic, serologic, or plasmatic parameters studied were registered, apart from thrombomodulin which showed significant variations between baseline and 1st-month values and 1st- and 3rd-month values. In conclusion, the evidence of significant variations of thrombomodulin values in the 1st month of therapy, which is considered to involve the highest risk of thrombosis, might support a role for thrombomodulin in this complex mechanism.

AB - Deep venous thrombosis (DVT) has been variably reported in multiple myeloma patients during treatment with thalidomide alone or in combination with chemotherapy or dexamethasone. With the aim of investigating this complication, we performed, on a cohort of 13 relapsed refractory MM patients treated with low-dose thalidomide (100 mg/day) and dexamethasone (20 mg p.o./day for 4 days every 2 weeks), a serial evaluation of different laboratory parameters implicated in DVT. No significant abnormalities in all genetic, serologic, or plasmatic parameters studied were registered, apart from thrombomodulin which showed significant variations between baseline and 1st-month values and 1st- and 3rd-month values. In conclusion, the evidence of significant variations of thrombomodulin values in the 1st month of therapy, which is considered to involve the highest risk of thrombosis, might support a role for thrombomodulin in this complex mechanism.

KW - Deep venous thrombosis

KW - Dexamethasone

KW - Multiple myeloma

KW - Thalidomide therapy

UR - http://www.scopus.com/inward/record.url?scp=4444308010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444308010&partnerID=8YFLogxK

U2 - 10.1007/s00277-004-0891-6

DO - 10.1007/s00277-004-0891-6

M3 - Article

VL - 83

SP - 588

EP - 591

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 9

ER -